China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with South Korea’s TiumBio Co., Ltd (KOSDAQ: 321550), securing exclusive development, regulatory filing, and commercialization rights to TiumBio’s drug candidate TU2670 in Greater China, including Hong Kong, Macau, and Taiwan.
Agreement Details
Under the agreement, Hansoh has the rights to develop and commercialize TU2670 for the treatment of endometriosis, fibroids, and other potential indications. TiumBio will receive a USD4.5 million upfront payment, a USD1.5 million technology transfer fee, and up to USD164 million in potential milestone payments, along with tiered royalties based on net sales.
Drug Profile
TU2670 is an oral non-peptide GnRH receptor antagonist that has shown a favorable safety and tolerability profile in early clinical trials. In China, Hengrui Medicine is also developing SHR7280, another GnRH receptor antagonist, which has been approved for study in prostate cancer and assisted reproduction.-Fineline Info & Tech
